US 11,942,187 B2
Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements
James D. Otvos, Apex, NC (US)
Assigned to LIPOSCIENCE, INC., Morrisville, NC (US)
Filed by Liposcience, Inc., Morrisville, NC (US)
Filed on Nov. 4, 2019, as Appl. No. 16/673,104.
Application 16/673,104 is a continuation of application No. 15/223,237, filed on Jul. 29, 2016, granted, now 10,504,610.
Application 15/223,237 is a continuation of application No. 11/746,812, filed on May 10, 2007, granted, now 9,435,870, issued on Sep. 6, 2016.
Claims priority of provisional application 60/746,894, filed on May 10, 2006.
Prior Publication US 2020/0066370 A1, Feb. 27, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/48 (2006.01); G01N 15/06 (2006.01); G01N 24/08 (2006.01); G01N 33/483 (2006.01); G01N 33/50 (2006.01); G01R 33/465 (2006.01); G16B 5/00 (2019.01); G16B 40/00 (2019.01); G16H 10/40 (2018.01); G16H 20/00 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G01N 15/00 (2006.01)
CPC G16B 5/00 (2019.02) [G01N 15/0656 (2013.01); G01N 24/08 (2013.01); G01N 33/4833 (2013.01); G01R 33/465 (2013.01); G16B 40/00 (2019.02); G16H 10/40 (2018.01); G16H 20/00 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G01N 2015/0065 (2013.01); G01N 2800/323 (2013.01); G01N 2800/324 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of determining a subject's risk of having and/or developing CHD, comprising:
obtaining a composite Nuclear Magnetic Resonance (NMR) spectrum of a biosample comprising blood, plasma, or serum of a subject;
deconvolving the composite NMR spectrum to obtain concentration measurement values of small and large HDL subclass particles in the biosample;
programmatically adjusting at least one of the NMR-derived small and large HDL subclass particle concentration measurement values based on a predetermined mathematical model, wherein the model comprises at least one weighting factor;
using the adjusted HDL subclass particle concentration measurement values to generate a CHD risk value; and
determining the subject's risk of having and/or developing CHD based on the generated CHD risk value.